Pro Chart

Vir Biotechnology Inc.

NasdaqGS: VIR · Real-Time Price · USD
8.96
+0.03 (0.34%)
At close: Aug 12, 2026, 3:59 PM

Vir Biotechnology Inc. (VIR) Stock Price, Analysis & Data

0.34%
Bid6.47
Market Cap1.52B
Revenue (ttm)303.23M
Net Income (ttm)-251.68M
Beta1.59
EPS (ttm)-1.78
PE Ratio (ttm)n/a
Forward PE-3.59
P/B (ttm)1.78
P/S (ttm)5.00
Earnings DateNov 4, 2026
Ask11.44
Volume896,152
Avg. Volume (20D)1,853,704
Open8.89
Previous Close8.93
Day's Range8.86 - 9.09
52-Week Range4.25 - 11.66
AnalystStrong Buy
Price Target20 (123.21%)
Dividendsn/a
Ex-Dividend Daten/a

About VIR

Vir Biotechnology, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutic products to treat and prevent serious infectious diseases in the United States and internationally. Its clinical development pipeline consists of product investigational therapies targeting hepatitis delta virus (HDV) and other solid tumors. The company's preclinical candidates include those targeting influenza A and B antibodies and antibody d...

Industry Biotechnology
Sector Healthcare
IPO Date Oct 11, 2019
Employees 367
Stock Exchange NasdaqGS
Ticker Symbol VIR
Full Company Profile

Financial Performance

In 2025, Vir Biotechnology's revenue was 66.52M, an increase of 4.41% compared to the previous year's 63.71M. Earnings were -437.99M, a decrease of -16.09%.

Financial Statements

Analyst Forecast

According to 9 analyst ratings, the average rating for VIR stock is "Strong Buy". The 12-month stock price forecast is 20, which is upside of 123.21% from the latest price.

Stock Forecasts

Earnings Surprise

Vir Biotechnology has released their quarterly earnings on Aug 5, 2026:
  • Revenue of $238.94M misses estimates by $0, with 23075.07% YoY growth.
  • EPS of 0.47 misses estimates by -0.43, with 158.75% YoY growth.
  • Vir Biotechnology Inc. is scheduled to release its earnings on Nov 4, 2026, during market hours.
    Analysts project revenue of ... Upgrade